Boston Scientific has bought the gynecology and urology portfolio of US-based medical device company Distal Access for an undisclosed amount.
The products acquired include the Resectr Tissue Resection Device, which is a disposable non-powered, hand-held and hand-driven system solution featuring a combination of the benefits of basic manual devices and complex electromechanical systems.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is used to remove uterine polyps which can cause abnormal uterine bleeding and infertility.
Boston Scientific urology and pelvic health senior vice-president David Pierce said: “The Resectr device is exactly the type of innovation we need to help make healthcare more cost-effective and accessible for physicians and their patients.
“This acquisition is part of our commitment to advance comprehensive solutions for women’s health that can help physicians provide high-quality care.”
Compatible with a range of hysteroscopes, the Resectr device enables treatment of polyps in an office, hospital or ambulatory surgery centre thereby reducing additional cost required.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe Resectr device will be a part of the Boston Scientific urology and pelvic health business which offers minimally invasive solutions for gynecologic surgery, including the Symphion System for uterine tissue removal and Genesys HTA System for the treatment of abnormal uterine bleeding.
Additionally, the urology and pelvic health portfolio features products which are used to address kidney stones, benign prostatic hyperplasia (BPH), erectile dysfunction, male incontinence and pelvic floor disorders.
